The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.
about
Functional analysis of Tpr: identification of nuclear pore complex association and nuclear localization domains and a role in mRNA exportAmino acid substitutions of coiled-coil protein Tpr abrogate anchorage to the nuclear pore complex but not parallel, in-register homodimerizationNucleocytoplasmic transport of proteins and poly(A)+ RNA in reconstituted Tpr-less nuclei in living mammalian cellsLocalization of nucleoporin Tpr to the nuclear pore complex is essential for Tpr mediated regulation of the export of unspliced RNA.Identification of protein p270/Tpr as a constitutive component of the nuclear pore complex-attached intranuclear filamentsTargeting the hepatocyte growth factor-cMET axis in cancer therapyAn overview of the c-MET signaling pathwayAdvanced gastric cancer: Current treatment landscape and future perspectivesProteins connecting the nuclear pore complex with the nuclear interiorOrchestrating the Selection and Packaging of Genomic RNA by Retroviruses: An Ensemble of Viral and Host FactorsTpr, a large coiled coil protein whose amino terminus is involved in activation of oncogenic kinases, is localized to the cytoplasmic surface of the nuclear pore complexRole of receptor tyrosine kinases in gastric cancer: new targets for a selective therapyDirect interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion.Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cellsThe potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion.Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells.Role of the nuclear envelope in genome organization and gene expression.Esophageal cancer alters the expression of nuclear pore complex binding protein Hsc70 and eIF5A-1.Tyrosine kinase inhibitors as cancer therapy.Activating MET kinase rearrangements in melanoma and Spitz tumours.Transforming activity of retroviral genomes encoding Gag-Axl fusion proteins.The Nuclear Matrix Protein Megator Regulates Stem Cell Asymmetric Division through the Mitotic Checkpoint Complex in Drosophila Testes.Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population.Expression of nuclear retinoid receptors in normal, premalignant and malignant gastric tissues determined by in situ hybridization.Nuclear pore proteins and cancerNucleoporin Nup98 mediates galectin-3 nuclear-cytoplasmic trafficking.MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer.New targeted therapies for gastric cancer.c-MET as a potential therapeutic target and biomarker in cancer.Aiding and abetting cancer: mRNA export and the nuclear pore.Role of c-mesenchymal-epithelial transition pathway in gastric cancer.Promise and challenges on the horizon of MET-targeted cancer therapeuticsPreclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma.A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
P2860
Q22008581-FA5D0A5F-3D15-4A62-8DB4-D26B2CD69350Q24291593-C82D41B9-27FA-469D-A88D-59FEC639CF25Q24294319-BA481C71-1978-48B4-9292-BB38E931F93DQ24302169-F411149D-A13D-42CD-A9D5-F013510F3085Q24318735-C605C18A-CD0C-4423-A95F-EB6940EB54FFQ24606259-6B95C90E-974C-4B59-9095-EF1FC75DADF7Q24633986-32497B50-23F3-48A1-A194-28B20B65783EQ26764934-DAD0B41F-43DC-490F-933C-35197EFD2585Q27937540-BE9B3D52-D0D6-4ADD-8199-FA5267DF9E8BQ28074165-658675AD-9CA6-41C1-BC2F-A9CC8DDDA9BFQ28118819-DED0594E-925E-4D9C-A09C-CD3CA76535D4Q28242840-21CD953D-1B4C-4B49-AC17-BC5D593816C4Q30445760-B7EA22CA-CC77-4035-A06F-D4D46D8FB37CQ31121236-DF244668-34FE-4DAC-A79D-92078BE43412Q33769429-B114DE4C-D858-4476-B335-C9094BFE3908Q33934433-C6A7D0D9-EC8E-4953-86B9-869729DAA0CFQ34236194-B509D1D1-49B8-4668-AAC9-FA26396158FDQ34482678-D6232286-01D1-4693-B207-61DFC8697E65Q34632599-06293A27-4AA3-4820-B5A0-17BE81C8B560Q34641660-7A20B10A-9341-4C7B-B002-7058C1BBCCFEQ35589206-DE908E44-3FE9-461B-B916-B3DFAA9DF84AQ35658282-A68350F3-3E44-4473-AD76-5551F892E05EQ35872635-2AC62505-E25F-4374-91DA-D2EE3C9AD267Q35880853-4CD5D106-7E6D-4E54-B7FA-69783E36AC4CQ36563092-3E810381-7CCC-4EE2-B79D-17B587991696Q36620052-F778528F-CDED-4A44-A8DA-93291E5ACB06Q37252910-90627ABE-C28F-434B-9C84-0B0974EDBF9CQ37398525-859398E4-FC45-4890-9E4E-1F7AC78844EAQ37597858-02D2DDD7-BBA5-4612-A40F-A4EB02E3C8ABQ37694731-7AFE220D-03F4-48F0-981D-16EDDA2976B6Q37853198-5E7ADCA9-F57A-4759-8984-15FDCA633F91Q37962905-65549F50-4F0E-4C7C-A76B-D281AD0D1FCCQ38098701-DBA8D5DC-0494-48F0-85E6-D6ACB0FA396AQ38424220-6AFBA923-9010-40D3-9C96-DCB40E9B7D5BQ38502350-8E6A3B77-DBE7-42BB-9940-A2F2A46B35B0Q38782345-9DA24681-6514-4CB3-803F-FAC0527DDAD4Q38824065-692571C2-D6ED-4185-9AE1-3F97A643F54AQ38833773-46E3233F-6A59-457E-9E16-090EC7F038F8Q38923535-2DCBF643-20AD-48E3-B852-A30AE855C93DQ39016480-B37C23F3-25C7-485F-988D-8DA96A472AA1
P2860
The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The TPR-MET oncogenic rearrang ...... rcinoma and precursor lesions.
@en
The TPR-MET oncogenic rearrang ...... rcinoma and precursor lesions.
@nl
type
label
The TPR-MET oncogenic rearrang ...... rcinoma and precursor lesions.
@en
The TPR-MET oncogenic rearrang ...... rcinoma and precursor lesions.
@nl
prefLabel
The TPR-MET oncogenic rearrang ...... rcinoma and precursor lesions.
@en
The TPR-MET oncogenic rearrang ...... rcinoma and precursor lesions.
@nl
P2093
P2860
P356
P1476
The TPR-MET oncogenic rearrang ...... rcinoma and precursor lesions.
@en
P2093
P2860
P304
P356
10.1073/PNAS.88.11.4892
P407
P577
1991-06-01T00:00:00Z